Adamas Pharma (ADMS) Announces Positive Data from ADS-5102 Phase 2 POC as MS-Related Treatment
Tweet Send to a Friend
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) announced positive findings from its Phase 2 proof-of-concept study designed to evaluate ADS-5102 (amantadine HCl) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
